Quick Answer
AtriCure, Inc. reported Total Revenue of $534.53 million for fiscal year 2025.
AtriCure, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $534.53M +14.9% |
$465.31M +16.5% |
$399.25M +20.8% |
$330.38M +20.4% |
$274.33M +32.8% |
$206.53M -10.5% |
| Revenue (ASC 606) | $534.53M +14.9% |
$465.31M +16.5% |
$399.25M +20.8% |
$330.38M +20.4% |
$274.33M +32.8% |
$206.53M -10.5% |
| Net Income | -$11.45M +74.4% |
-$44.70M -46.8% |
-$30.44M +34.5% |
-$46.47M -192.6% |
$50.20M +204.2% |
-$48.16M -36.8% |
| Diluted EPS | -$0.24 +74.7% |
-$0.95 -43.9% |
-$0.66 +35.3% |
-$1.02 -193.6% |
$1.09 +195.6% |
-$1.14 -21.3% |
| Total Assets | $654.18M +7.4% |
$609.33M -0.7% |
$613.93M +4.9% |
$585.45M -4.9% |
$615.31M -13.9% |
$714.54M +28.1% |
| Cash and Equivalents | $167.43M +36.4% |
$122.72M +45.6% |
$84.31M +45.1% |
$58.10M +33.1% |
$43.65M +4.1% |
$41.94M +47.3% |
| Long-Term Debt | $61.87M +0.0% |
$61.87M +1.4% |
$61.00M +7.3% |
$56.83M -4.9% |
$59.74M +11.8% |
$53.44M -10.4% |
| Stockholders Equity | $491.94M +6.7% |
$460.97M -1.1% |
$466.17M +2.1% |
$456.75M -5.6% |
$483.76M +17.3% |
$412.39M +66.7% |
| R&D Expense | $99.21M +3.2% |
$96.18M +30.1% |
$73.92M +28.9% |
$57.34M +18.2% |
$48.51M +12.6% |
$43.07M +4.5% |
| Operating Income | -$9.45M +76.4% |
-$40.01M -50.0% |
-$26.68M +37.5% |
-$42.67M -177.3% |
$55.20M +224.8% |
-$44.23M -33.5% |
| Gross Profit | $400.78M +15.3% |
$347.52M +15.7% |
$300.37M +22.1% |
$245.94M +19.5% |
$205.86M +37.9% |
$149.31M -12.3% |
| Shares Outstanding | 49.79M +1.9% |
48.87M +2.8% |
47.53M +2.1% |
46.56M +1.2% |
46.02M +1.5% |
45.35M +14.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $134.27M | +15.8% | -1.4% |
| Revenue (ASC 606) | September 30, 2025 | $134.27M | +15.8% | -1.4% |
| Net Income | September 30, 2025 | -$267.0K | +96.6% | +95.7% |
| Diluted EPS | September 30, 2025 | -$0.01 | +94.1% | +92.3% |
| Total Assets | September 30, 2025 | $635.44M | +3.3% | +4.4% |
| Cash and Equivalents | September 30, 2025 | $147.87M | +13.4% | +25.5% |
| Long-Term Debt | September 30, 2025 | $61.87M | +0.0% | +0.0% |
| Stockholders Equity | September 30, 2025 | $476.51M | +2.5% | +2.6% |
| R&D Expense | September 30, 2025 | $22.89M | +9.2% | -21.8% |
| Operating Income | September 30, 2025 | $208.0K | +102.8% | +103.4% |
| Gross Profit | September 30, 2025 | $101.33M | +16.8% | -0.1% |
| Shares Outstanding | September 30, 2025 | 49.71M | +2.0% | +0.0% |
- AtriCure, Inc. reported Total Revenue of $534.53 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +14.9% in Total Revenue compared to the prior fiscal year.
- AtriCure, Inc. reported Revenue (ASC 606) of $534.53 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +14.9% in Revenue (ASC 606) compared to the prior fiscal year.
- AtriCure, Inc. reported Net Income of -$11.45 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +74.4% in Net Income compared to the prior fiscal year.
- AtriCure, Inc. reported Diluted EPS of $0.24 per share (loss) for fiscal year 2025.
- AtriCure, Inc. showed an increase of +74.7% in Diluted EPS compared to the prior fiscal year.
- AtriCure, Inc. reported Total Assets of $654.18 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +7.4% in Total Assets compared to the prior fiscal year.
- AtriCure, Inc. reported Cash and Equivalents of $167.43 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +36.4% in Cash and Equivalents compared to the prior fiscal year.
- AtriCure, Inc. reported Long-Term Debt of $61.87 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +0.0% in Long-Term Debt compared to the prior fiscal year.
- AtriCure, Inc. reported Stockholders Equity of $491.94 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +6.7% in Stockholders Equity compared to the prior fiscal year.
- AtriCure, Inc. reported R&D Expense of $99.21 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +3.2% in R&D Expense compared to the prior fiscal year.
- AtriCure, Inc. reported Operating Income of -$9.45 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +76.4% in Operating Income compared to the prior fiscal year.
- AtriCure, Inc. reported Gross Profit of $400.78 million for fiscal year 2025.
- AtriCure, Inc. showed an increase of +15.3% in Gross Profit compared to the prior fiscal year.
- AtriCure, Inc. reported Shares Outstanding of 49.79 million shares for fiscal year 2025.
- AtriCure, Inc. showed an increase of +1.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: